503A Price Audit Verified: Semaglutide $49/mo · Tirzepatide $99/mo ($0 Platform Membership · All Doses Locked) Claim $49 Rate →
Losing Weight RX Open-Data Desk
Zero-Dependency Pharmacoeconomic Tool · Powered by DOI 10.5281/zenodo.24139333

Oral Sublingual vs. Weekly Injectable GLP-1 Cost & Absorption Estimator (2026)

Compare needle-free daily sublingual dissolving GLP-1 tablets ($49 1st month / $149 ongoing) against weekly $49 Semaglutide / $99 Tirzepatide injections and $969 retail oral tablets.

LWR Protocol Total
$1,688
Competitor Sublingual / Retail
$3,516
Your Verified Savings
$1,828

Underlying Empirical Dataset Citation

All default provider rates, PBM thresholds, and bioavailability coefficients in this tool are drawn directly from our open-access CC-BY-4.0 dataset (metabolic-cellular-delivery-bioavailability-cost-2026 · Academic DOI 10.5281/zenodo.24139333).

Ready to Lock In Your Verified Flat Rate?

$0 platform membership, $0 high-dose escalation surcharges, and free express cold-chain shipping.

Compare Needle-Free Oral GLP-1 ($49 1st Mo) →

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Oral Sublingual vs. Weekly Injectable GLP-1 Cost & Absorption Estimator (2026) is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023). Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet (London, England), 402(10403), 693-704. https://doi.org/10.1016/S0140-6736(23)01127-3
  2. Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., & Feldman, H. H. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet (London, England), 407(10544), 2167-2179. https://doi.org/10.1016/S0140-6736(26)00459-9
  3. Harvard Health Publishing, Harvard Medical School. (2024). How does Ozempic work? Understanding GLP-1s for diabetes, weight loss, and beyond. https://www.health.harvard.edu/staying-healthy/how-does-ozempic-work-understanding-glp-1s-for-diabetes-weight-loss-and-beyond
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. Rosenstock, J., Yabe, D., Cox, D., Li, J., Denning, M., Wu, W. S., Liu, R., & Zhao, Y. (2026). Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet (London, England), 407(10534), 1147-1160. https://doi.org/10.1016/S0140-6736(26)00202-3
  6. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss